Home    Back

Atomoxetine    (DrugBank: Atomoxetine)

3 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease5
8Huntington disease1
13Multiple sclerosis/Neuromyelitis optica1

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02879136
(ClinicalTrials.gov)		December 201623/6/2016TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's DiseaseTAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot StudyParkinson's Disease, IdiopathicDrug: Methylphenidate;Other: Physical Therapy;Drug: AtomoxetineHubert FernandezNULLRecruiting18 Years90 YearsAll42Early Phase 1United States
2NCT03651856
(ClinicalTrials.gov)		January 20132/7/2018Atomoxetine for Freezing of Gait in Parkinson's DiseaseA Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's DiseaseParkinson's Disease;Freezing of GaitDrug: ATM FOG in PDMedical University of South CarolinaNULLCompleted18 Years80 YearsAll10Phase 3United States
3NCT01738191
(ClinicalTrials.gov)		November 201228/11/2012Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)Parkinson's Disease;Cognitive ImpairmentDrug: Atomoxetine;Drug: PlaceboMedical University of South CarolinaMichael J. Fox Foundation for Parkinson's ResearchCompleted35 Years75 YearsAll30Phase 2United States
4NCT00286949
(ClinicalTrials.gov)		January 6, 20053/2/2006Treatment of Executive Dysfunction in Parkinson's DiseaseAtomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label StudyParkinson's DiseaseDrug: AtomoxetineJohns Hopkins UniversityEli Lilly and CompanyCompleted21 Years65 YearsAll12N/AUnited States
5NCT00304161
(ClinicalTrials.gov)		July 200415/3/2006Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's DiseaseDepression Diagnosis and Treatment in Parkinson DiseaseDepressive Disorder;Parkinson DiseaseDrug: Atomoxetine;Drug: PlaceboUniversity of PennsylvaniaNational Institute of Mental Health (NIMH)Completed30 Years79 YearsAll55Phase 4United States

Back to top


8. Huntington disease    [ 197 clinical trials,   171 drugs,   (DrugBank: 54 drugs),   82 drug target genes,   144 drug target pathways]
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 197 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00368849
(ClinicalTrials.gov)		November 200524/8/2006Atomoxetine and Huntington's DiseaseAtomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover StudyHuntington Disease;ChoreaDrug: atomoxetine;Drug: Matching PlaceboUniversity of IowaEli Lilly and CompanyCompleted18 Years65 YearsAll20Phase 2United States

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03091400
(ClinicalTrials.gov)		March 16, 201716/3/2017Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple SclerosisMemory Disorders;Multiple SclerosisDrug: Atomoxetine;Drug: PlaceboIcahn School of Medicine at Mount SinaiNULLCompleted21 Years60 YearsAll11Phase 2United States

Back to top